Cognision

Cognision operates at the intersection of neurodiagnostic devices, digital health, and clinical-trial research. Its COGNISION System records and analyzes EEG, quantitative EEG, and event-related potentials to measure cognitive brain function, with potential applications spanning cognitive disorders and pharmaceutical research. Cognision360 extends this capability into a web-based workflow for neurobiomarker acquisition, processing, and analysis in CNS trials, addressing data integration and trial-output needs rather than offering only a standalone measurement device. The company’s partnerships illustrate distinct use cases: Kynexis is deploying the system in a schizophrenia trial, while the SOMNOmedics collaboration adds sleep-related measurement through polysomnography. Participation in a ten-pharmaceutical-company biomarker consortium also connects its work to broader efforts to qualify EEG/ERP measures for drug development. The available profile does not identify named direct competitors, so a company-by-company comparison is not supportable. Its differentiation is most clearly evidenced by combining objective EEG/ERP assessment with trial-oriented services and a unified software platform. The company is listed in the 11–50 employee range, but market share and commercial scale are not established by the available figures.

Cognision’s trajectory combines a long operating history with a more visible expansion of clinical-trial products and partnerships in 2025–2026. Founded in 2004, the company’s recorded financing totals $2,115,812 across three rounds: a $100,000 grant dated Feb 4, 2004, a Mar 3, 2008 venture round with no amount specified, and a $2,015,812 venture round on Jul 19, 2018. The 2018 round is its latest recorded financing, so the recent milestones appear to reflect product and collaboration activity rather than a newly documented funding cycle. A notable inflection point came on Sep 24, 2025 with the SOMNOmedics partnership, followed by the Kynexis Phase 2 trial collaboration announced on Nov 14, 2025. The Feb 3, 2026 launch of Cognision360 broadened the offer from neurodiagnostic measurement toward integrated biomarker data workflows. By June 2026, consortium participation and ketamine-response research further showed application of EEG/ERP methods in CNS drug development.